Lessons learned from implementing in AI at regulated medical device manufacturer, ResMed. This includes top 5 challenges and ...

The Australian sharemarket finished lower as broad losses across the exchange offset a rally for lithium miners, on an ...

The two different program files are available only in the 64-bit operating system. The 32-bit operating system will have only a single program file folder. The main difference is that the program file ...

Gift 5 articles to anyone you choose each month when you subscribe. Sleep apnea device maker ResMed will expand its American manufacturing operations and open a new facility in Indianapolis in 2027 ...

Hello, and welcome to the Q1 Fiscal Year 2026 ResMed Earnings Conference Call. My name is Kevin. I'll be your operator for today's call. [Operator Instructions] Also, please note, this conference call ...

Fractus, a company specializing in geometry-based antenna technology and IP licensing, has filed a patent infringement suit against respiratory leader ResMed. The complaint was filed in the United ...

Morgan Stanley analyst David Bailey maintained a Buy rating on CSL today and set a price target of A$256.00.

Powered by rising margins, global growth, and confidence from management, this sleep tech stock is turning heads again. The New York Stock Exchange-listed ResMed Inc (NYSE: RMD) share price surged ...

SAN DIEGO – Resmed CEO Mick Farrell addressed the latest potential threats to the CPAP therapy market during a recent webcast: The resurgence of Medicare’s competitive bidding program and the ...

CEO Michael J. Farrell announced that ResMed delivered "another very strong quarter, closing out fiscal year 2025 with excellent results," highlighting 10% year-over-year reported revenue growth and ...

Revenue: $1.35 billion, a 10% increase year-over-year. Gross Margin: 61.4%, an expansion of 230 basis points year-over-year. Free Cash Flow: $1.7 billion for fiscal year 2025. Net Income: Increased by ...

Gift 5 articles to anyone you choose each month when you subscribe. Resmed has beaten full-year earnings and revenue forecasts on the back of strong global sales of its devices to treat sleep apnoea, ...